Antigen-specific T cell response from dendritic cell vaccination using side population cell-associated antigens targets hepatocellular carcinoma
- 307 Downloads
Dendritic cell (DC) vaccination targeting cancer stem cells is an effective way to suppress tumor progression and reduce the metastasis and recurrence. In the present study, we explored the suitability of side population (SP) cells as source of antigens for DC vaccination against hepatocellular carcinoma (HCC) in a mouse model. In this study, we identified the “stem-like” characteristics of SP cells in the MHCC97 and Hepa 1-6 HCC cell lines. We found that SP cells express high levels of tumor-associated antigens and MHC class I molecules. Although loading with cell lysates did not change the characteristics of DCs, SP cell lysate-pulsed DCs induced antigen-specific T cell responses, including T cell proliferation and increased IFN-γ production by stimulated CD8+ T cells. We investigated the cytotoxicity of T cells stimulated by SP cell lysate-pulsed DCs in nude mice co-injected with MHCC97 cells. To mimic the in vivo environment, we also confirmed the result in mouse HCC cell line Hepa 1-6 induced tumor-bearing C57/BL6 immune competent mice, and we demonstrated that vaccination with DCs loaded with Hepa 1-6 SP cell lysates could induce a T cell response in vivo and suppress the tumor growth. Our results may have applications for anti-HCC immunotherapy by targeting the cancer stem cells and may provide new insight for cancer vaccines.
KeywordsDendritic cells Side population cells Cancer stem cells Hepatocellular carcinoma Cytotoxic T lymphocytes
We thank Dr. Ben Ma and Wei Sun for their help in the experiment. The experiment was supported by National Natural Science Foundation (81201926).
Conflicts of interest
- 6.Ernst B, Anderson KS. Immunotherapy for the treatment of breast cancer. Curr Oncol Rep. 2015;17:5.Google Scholar
- 10.Finocchiaro G, Pellegatta S. Immunotherapy with dendritic cells loaded with glioblastoma stem cells: From preclinical to clinical studies. Cancer Immunology, Immunotherapy. 2015;65:101–9.Google Scholar
- 17.Shen H, Shao H, Chen X, Wu F, Wang H, Huang Z, et al. Identification of a novel HLA-A2-restricted mutated Survivin epitope and induction of specific anti-HCC CTLs that could effectively cross-recognize wild-type Survivin antigen. Cancer Immunol Immunother. 2013;62:393–403.CrossRefPubMedGoogle Scholar
- 19.Trojan A, Witzens M, Schultze JL, Vonderheide RH, Harig S, Krackhardt AM, et al. Generation of cytotoxic T lymphocytes against native and altered peptides of human leukocyte antigen-A*0201 restricted epitopes from the human epithelial cell adhesion molecule. Cancer Res. 2001;61:4761–5.PubMedGoogle Scholar
- 27.Pang YB, Zhong JH, Luo XL, Ou C, Guo Z, Xiang BD, Peng NF, Li LQ. Clinicopathological characteristics and liver stem cell marker expression in hepatocellular carcinoma involving bile duct tumor thrombi. Tumour Biol. 2015. doi: 10.1007/s13277-015-4446-3.